Trial NCT05142319
Publication Poh XY, Clin. Infect. Dis., 2022
Primary outcome on the report: Whether a heterologous mRNA-1273 COVID-19 vaccine booster leads to non-inferior humoral immunity against wild-type SARSCoV-2 and/or VOCs at day 28 compared with homologous BTN162b2

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.